Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evoke Pharma ( (EVOK) ) has provided an announcement.
On July 9, 2025, Evoke Pharma announced it received a Notice of Allowance from the USPTO for a U.S. patent application covering the use of GIMOTI® for moderate to severe gastroparesis symptoms. This patent, expected to expire in December 2036, will extend GIMOTI’s market exclusivity, reinforcing its intellectual property estate and potentially enhancing its market position. The announcement underscores Evoke’s commitment to advancing treatment options for gastroparesis, a chronic condition affecting millions worldwide, and highlights GIMOTI’s unique position as a non-oral treatment option.
Spark’s Take on EVOK Stock
According to Spark, TipRanks’ AI Analyst, EVOK is a Neutral.
Evoke Pharma’s stock score reflects a company facing financial difficulties despite notable revenue growth. The financial performance heavily weighs down the score due to persistent losses and cash flow issues. Technical analysis suggests bearish trends, and the valuation is unattractive with a negative P/E ratio. However, the earnings call provided a positive outlook, highlighting strategic initiatives and growth prospects, partially balancing the overall score.
To see Spark’s full report on EVOK stock, click here.
More about Evoke Pharma
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The company developed, commercialized, and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Average Trading Volume: 15,602
Technical Sentiment Signal: Sell
Current Market Cap: $3.96M
For an in-depth examination of EVOK stock, go to TipRanks’ Overview page.